An observational study in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex, sponsored by University Hospital, Tours. Completed at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-29.
Sponsored by University Hospital, Tours · Observational
This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis. The controls are patients followed in neurology at the CHU of Tours for a tuberous sclerosis complex without lymphangioleiomyomatosis, the healthy volunteers are women with neither pulmonary nor renal pathology and recruited at the clinical investigation centre of the CHU of Tours.
48 studies on the registry are indexed under Lymphangioleiomyomatosis; 11 are open to participants now.
This study's enrollment of 19 is below the median of 200 across 17 observational studies indexed under Lymphangioleiomyomatosis.
Browse Lymphangioleiomyomatosis studies →University Hospital, Tours is the lead sponsor of 306 studies on the registry; 78 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult female patients with lymphangioleiomyomatosis or with tuberous sclerosis complexwithout AML or healthy volunteers
Inclusion criteria for patients with lymphangioleiomyomatosis
Inclusion criteria for healthy female volunteers
Inclusion criteria for tuberous sclerosis complex patients without lymphangioleiomyomatosis
Non-inclusion criteria
no intervention administered. Recruitment in pneumology department
Other: 24h urine · Other: urine sample
no intervention administered. Recruitment in neurology department
Other: 24h urine · Other: urine sample
no intervention administered. Recruitment in clinical investigation centre
Other: 24h urine · Other: urine sample
Urine samples will be collected at home over 24 hours
A urine sample of 20cc will be collected
urine cathepsin K proteins levels
comparison of urine cathepsin K protein levels in the 3 groups
Time frame: inclusion visit
urine cathepsin K activity
comparison of urine cathepsin K activity in the 3 groups
Time frame: inclusion visit
urinary quantity of cystatin C
comparison of urine cystacin C quantity in the 3 groups
Time frame: inclusion visit
urinary quantity C and N-telopeptides of type 1 collagen
comparison in the 3 groups
Time frame: inclusion visit
serum level of chondroitin sulphates
measurement in lymphangioleiomyomatosis patients
Time frame: inclusion visit
renal angiolipomas
measurement of the size of renal angiomyolipomas in lymphangioleiomyomatosis patients
Time frame: inclusion visit
FEV1 measurement
most recent FEV1 measurement as % of predicted value in lymphangioleiomyomatosis patients
Time frame: inclusion visit
VEGF-D measurement
most recent measurement of VEGF-D blood levels in lymphangioleiomyomatosis patients
Time frame: inclusion visit
T-score measurement
T-score measurement of the most recent bone densitometry in lymphangioleiomyomatosis patients
Time frame: inclusion visit
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.